Meridian Bioscience Stock

Meridian Bioscience OCF Margin

The Operating Cash Flow Margin of Meridian Bioscience (VIVO) as of Sep 11, 2026 is 24.73 %. In the previous year, Operating Cash Flow Margin was 21.03 % — a change of 17.58% (higher).

OCF Margin

24.73 %

YoY

17.58%

Last updated:

Operating Cash Flow Margin of Meridian Bioscience is 2026 24.73 % . Operating Cash Flow Margin of Meridian Bioscience was 2025 21.03 % . It decreases by 17.58% higher compared to the previous year.

The Meridian Bioscience OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2015
21.98 USD
Jan 1, 2016
18.98 USD
Jan 1, 2017
20.60 USD
Jan 1, 2018
16.28 USD
Jan 1, 2019
18.00 USD
Jan 1, 2020
18.91 USD
Jan 1, 2021
21.03 USD
Jan 1, 2022
24.73 USD
The Meridian Bioscience OCF Margin history
YEAROCF MarginYoY
24.73 %+17.58%
21.03 %+11.22%
18.91 %+5.07%
18.00 %+10.55%
16.28 %-20.95%
20.60 %+8.52%
18.98 %-13.63%
21.98 %+8.45%
20.26 %
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Operating Cash Flow Margin of Meridian Bioscience is 24.73 % in 2026.

Operating Cash Flow Margin of Meridian Bioscience changed from 21.03 % to 24.73 %, representing a 17.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Meridian Bioscience

All Key Metrics — Meridian Bioscience